Artivion (NYSE:AORT) CEO James Mackin Sells 17,887 Shares

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 17,887 shares of Artivion stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $675,770.86. Following the sale, the chief executive officer owned 947,275 shares in the company, valued at $35,788,049.50. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Stock Performance

NYSE AORT traded down $0.21 during trading hours on Wednesday, hitting $38.41. The company had a trading volume of 460,494 shares, compared to its average volume of 418,663. The business has a 50 day moving average of $41.42 and a 200-day moving average of $42.92. The company has a market cap of $1.84 billion, a PE ratio of 192.06 and a beta of 1.60. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.Artivion’s revenue was up 19.2% compared to the same quarter last year. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company-level growth narrative: coverage highlights Artivion’s portfolio expansion that could broaden addressable markets and support longer‑term revenue growth. Portfolio Expansion Sets New Narrative
• Positive Sentiment: Earnings beat: the company recently topped revenue and EPS estimates (reported Feb. 12), which underpins the fundamental bull case for margin and top‑line momentum. Artivion Tops EPS
• Positive Sentiment: Analyst/institutional support: consensus rating sits at “Moderate Buy” with multiple firms maintaining buy/outperform calls and institutions (notably Invesco) increasing positions — a source of demand and validation for investors. Artivion Receives Consensus Rating
• Neutral Sentiment: Investor event: management will present at the Oppenheimer Healthcare MedTech & Services conference (virtual fireside chat) — potential catalyst if management provides new guidance or commercialization updates, but outcome is uncertain. Oppenheimer Conference Participation
• Neutral Sentiment: Technical/market context: trading is below the 50‑day ($41.59) and 200‑day ($42.95) moving averages and intraday volume is modestly above average — creates short‑term downside risk even as fundamentals are supportive. MarketBeat – Artivion Stock Data
• Negative Sentiment: Clustered insider selling: several senior executives (including CEO James P. Mackin, EVP Lance Berry and other officers) reported sizeable sales on March 2 — markets often interpret concentrated insider disposals as a negative near‑term signal despite large residual holdings. Insider Selling Alert SEC Form 4 – Mackin

Analyst Ratings Changes

A number of equities analysts have recently commented on AORT shares. Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Canaccord Genuity Group lowered their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Oppenheimer restated an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Citizens Jmp raised their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Hedge Funds Weigh In On Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Invesco Ltd. lifted its holdings in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares during the period. XTX Topco Ltd acquired a new stake in Artivion in the fourth quarter valued at $746,000. Susquehanna Portfolio Strategies LLC boosted its position in shares of Artivion by 21.5% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock worth $1,849,000 after purchasing an additional 7,186 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of Artivion during the 4th quarter worth $248,000. Finally, Millennium Management LLC grew its stake in shares of Artivion by 1.0% during the 4th quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after purchasing an additional 893 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.